New Data Presentation at Breast Cancer Symposium
Olema Pharmaceuticals, Inc. (Olema Oncology, NASDAQ: OLMA), a pioneering company in biopharmaceuticals, is set to unveil new findings from the Phase 1b/2 clinical study of palazestrant (OP-1250) combined with ribociclib at an important breast cancer symposium. Held at the Henry B. Gonzalez Convention Center, this Symposium attracts notable minds in the field dedicated to advancing cancer treatments.
Details of the Poster Presentation
The title of the poster that Olema will present emphasizes a significant aspect of their research: "A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, HER2-negative (ER+/HER2-), advanced or metastatic breast cancer." This study seeks to shed light on the efficacy and safety of this combination therapy.
Poster Session Information
This noteworthy presentation is scheduled for December 11, at a highly anticipated session from 5:30 to 7:00 p.m. CT. Attendees can find the poster showcased in Halls 2-3, where numerous other critical findings will be shared.
Conference Call Engagement
In addition to the poster presentation, Olema is hosting a conference call intended for investors and interested parties. This interactive session will occur on December 10 at 8:00 a.m. ET. By registering, participants will have the opportunity to delve deeper into the data being presented.
Understanding Palazestrant (OP-1250)
Palazestrant (OP-1250) represents a groundbreaking approach in treatment for breast cancer, functioning as a dual-action agent. Not only does it perform as a complete estrogen receptor (ER) antagonist, but it also acts as a selective ER degrader. This dual functionality is particularly relevant for patients with recurrent, locally advanced, or metastatic ER-positive (ER+), HER2-negative breast cancer, showcasing Olema's commitment to innovation.
Clinical Trial Outcomes
Through intensive preclinical studies, palazestrant has proven its ability to inhibit transcriptional activity in both wild-type and mutant forms of breast cancer cells. Efficacy has been observed during ongoing clinical trials, where the drug exhibited promising anti-tumor activity and favorable pharmacokinetics, which are crucial indicators of treatment success.
Fast Track Designation by FDA
Further highlighting the importance of palazestrant, the U.S. Food and Drug Administration (FDA) has granted it Fast Track designation to expedite its development for treating metastatic breast cancer that has progressed despite previous therapies. This designation underscores the drug's potential to improve patient outcomes significantly.
About Olema Oncology and Their Mission
Olema Oncology is steadfast in its mission to elevate the standard of care for breast cancer patients by developing innovative therapies tailored to their needs. With a strong clinical pipeline, Olema is not only advancing palazestrant (OP-1250) but is also exploring other promising compounds like KAT6 inhibitor (OP-3136).
Headquarters and Company Operations
Headquartered in San Francisco with additional operations in Cambridge, Massachusetts, Olema is well-positioned to drive research forward. Their focus on developing targeted treatments ensures continuous improvement in the care and outcomes for patients battling breast cancer.
Frequently Asked Questions
What is Olema Oncology focusing on?
Olema Oncology is dedicated to discovering and developing targeted therapies for breast cancer.
What data will Olema present at the symposium?
Olema will present findings from their study on palazestrant combined with ribociclib.
When is the conference call related to these findings?
The conference call will happen on December 10 at 8:00 a.m. ET.
What is the significance of palazestrant?
Palazestrant is a novel treatment for advanced ER+/HER2- breast cancer with dual-action capabilities.
How can I find more about Olema's research?
For further insights, visit Olema’s website for detailed information on their clinical trials and studies.
